Recent Company News

• 08:05 AM ET Dec 10, 2025
  

  NuCana presents latest data for NUC-7738 in patients with PD-1-Resistant melanoma ($4.28, 0.00)

• 07:59 AM ET Dec 10, 2025
  

  NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

• 04:08 PM ET Nov 13, 2025
  

  NuCana reports Q3 EPS 0.0p vs year-ago (0.07p) ($3.49, 0.00)

• 08:08 AM ET Nov 05, 2025
  

  NuCana announces grant of composition-of-matter patent for NUC-7738 in China ($3.63, 0.00)

• 08:00 AM ET Nov 05, 2025
  

  NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China

• 08:39 AM ET Oct 18, 2025
  

  NuCana presents data on NUC-7738 in combination with PD-1 inhibitors using primary patient-derived organoids and autologous tumor-infiltrating lymphocytes at ESMO ($5.07, 0.00)

• 08:03 AM ET Oct 14, 2025
  

  NuCana announces data for NUC-3373 in combination with anti-PD-1 therapy ($5.78, 0.00)

• 03:37 PM ET Sep 16, 2025
  

  NuCana research article on NUC-3373 drug candidate published in PLOS ONE journal ($4.56, +0.06)

• 04:08 PM ET Aug 20, 2025
  

  NuCana reports Q2 EPS 0.0p vs year-ago (0.1p) ($3.11, 0.00)

• 04:06 PM ET Aug 01, 2025
  

  NuCana announces ADS ratio change from one ADS, representing twenty-five ordinary shares, to one ADS representing five thousand ordinary shares, effective 11-Aug-25 ($0.04, 0.00)